Contribution ID: d81dcba2-9378-4d7e-bdb5-8ddfc31c4500

Date: 20/02/2017 12:16:46

Mid-term evaluation of the Third Health Programme (2014-2020)

Fields marked with * are mandatory.

INTRODUCTION

The EU ensures that human health is protected as part of all its policies, and to work with its Member States to improve public health, prevent human illness and eliminate sources of danger to physical and mental health. However, the EU Member States have the primary responsibility for formulating and implementing health policy and delivering healthcare services. The EU's competence only extends to supporting, coordinating or supplementing actions of the Member States.

One of the main ways in which the EU supports, coordinates and supplements actions by the Member States is the third programme for the Union's action in the field of health (2014-2020) (hereinafter: "3HP"). The 3HP provides financial support for actions to address a number of important health-related challenges facing European citizens, governments and health systems. The 3HP supports action across the EU from public authorities, research and health institutions, NGOs, international organisations and − in certain cases − private companies. The total budget for the seven years of its duration is €449.4 million. The 3HP addresses major health challenges facing MS from risk factors (such as use of tobacco and harmful use of alcohol) to chronic and rare diseases, responding to cross border health threats (e.g. Ebola and Zika viruses) as well as ensuring innovation in public health to name just a few areas. For more information on the 3HP, please visit the websites of DG SANTE or CHAFEA.

This consultation is an opportunity for any interested parties to express their views and opinions on the 3HP. It is a part of the ongoing mid-term evaluation of the 3HP. The consultation covers:

- The objectives and priorities of the 3HP, and the extent to which these are appropriate and in line with health needs in the EU
- The way the 3HP is implemented, and the extent to which this is effective and efficient
- The overall added value and usefulness of the 3HP

The results of the public consultation will be used together with other evidence to inform the mid-term evaluation of the 3HP. The European Commission will publish a Staff Working Document, including a summary of the results of the consultation, in the second half of 2017.

* Privacy Statement

Before completing the form, please read carefully the <u>privacy statement to conform to European data protection regulations</u>.

I have read and accept the terms and conditions related to this meeting

In case you wish to contact the Unit responsible for the event, please send an email to: <u>SANTE-HEALTH-PROGRAMME@ec.europa.eu</u>

I. KNOWLEDGE OF AND EXPERIENCE WITH THE 3HP

1.1. How would you describe the extent of your knowledge of:

	Detailed, in-depth knowledge	Some knowledge	Only very basic knowledge	No knowledge at all
*EU health policy?	•	•	0	•
*The 3HP?	0	•	0	0

*1.2. Are you working on health issues that are closely related to (any of) the ones supp	orted by
the Health Programme?	

Yes	3
-----	---

*1.3. Are you aware of any activities that were funded by the 3HP that are relevant to your work?

O No

O No

1.4	4. Have you ever consulted, used, or participated in any of the results, services or products
S	stemming from activities supported by previous Health Programmes? Please tick the following
е	examples, as appropriate:

The Commission encourages dissemination of Health Programme outputs and results, however linking to the following external websites from this webpage should not be taken as an endorsement of any kind by the European Commission.

	The European Code Against Cancer
	European screening guidelines on Breast cancer
	European screening guidelines on Colorectal cancer
	European screening guidelines on Cervical cancer
	The Orphanet database and recommendations for rare diseases
	The Eudamed database for medical devices (only accessible to Member State authorities)
	The Euripid database for the pricing of medicines
	Materials on health technology assessment
	Training packages, e.g. on <u>cancer screening</u> , <u>migrants' and refugees' health</u> , capacity building in the preparation and response against health threats in <u>air</u> and <u>sea</u> travel
	Best practices for tackling health inequalities
1	Best practices for the diagnosis and treatment of HIV/AIDS, tuberculosis and hepatitis
	Scientific Opinions from the <u>Independent Scientific Committees</u>
	Advice from the Expert Panel for investing in health
	Information campaigns (e.g. <u>Ex-smokers are unstoppable</u>)
	Reports (e.g. <u>Health at a Glance Europe</u> , The Economics of prevention, Country Health Reports, EU Health Report, different Reports on the monitoring of health strategies on nutrition, alcohol etc.)
	Comparable health data (e.g. <u>ECHI indicators</u>)
	Others
Others	s, please explain
	Have you or the organisation / institution you represent ever applied for funding from the and/or its predecessors?
•	Yes, I/we have applied for funding from the 3HP
0	No, I/we have never applied for funding from the 3HP
0	Don't know

1.6. If you have never applied for funding from the 3HP, please tell us why (tick all that apply)
The opportunities and activities are not relevant for me and/or my organisation
Lack of information on opportunities
Lack of information on how to apply
The co-funding rates are not attractive enough
Excessive administrative burden
Lack of language skills
Lack of partners in other European countries
Other, please specify
Other (please specify)
we applied as partners

1.7. The 3HP is supporting cooperation at EU level between relevant health organisations, national health authorities, academia and non-governmental bodies. To what extent do you agree with the following statements?

	Strongly	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Don't know
*The cooperation is essential and should be maintained	•	0	•	•	•	•
*The 3HP should be expanded to include other health areas	•	•	•	•	•	•
*In practice, the 3HP's results (at least at this mid- term stage) are not visible and the cooperation should be abandoned	©	©	©	©	•	©

* 1.8. In your opinion, what do you consider to be the main way(s) in which the 3HP is contributing (or could contribute) to addressing health-related challenges?

- * building consensus on proven and evidence based approaches
- *supporting exchange of information and experience accross countries for more effective approaches between agencies in different countries, civil society, professional bodies etc
- * supporting innovation via pilots
- * fostering partnerships between stakeholders
- * supporting the harmonisation (upward not downwards) data collection and addressing important gaps in data
- *supporting technical assistance to national authorities
- * rapid reaction projects to address emerging problematic situations

1.9. What are the main aspects (if any) that need to be changed or improved in your opinion?

- * civil society involvement has improved. However, it should not only be involved in the dissemination activities but also in content work. Its work should be adequately financially compensated.
- * sustainability of 3 year projects is a challenge, especially in a environment of decreasing funding at national level. Sustainability should be tackled from the start
- *uptake of project tools and findings by stakeholders and policy makers
- * there are sometimes requirements from the Commission/chafea that are not tailored/relevant to the subject of the project.

II. THE 3HP OBJECTIVES AND PRIORITIES

The 3HP aims to address a number of important health-related challenges facing EU citizens, governments and health systems. To do this, it pursues a series of objectives and thematic priorities, please see the factsheet about the 3HP for more information.


2.1. Do you think the EU should provide funding for actions in order to...?

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Don't know
*promote health, prevent diseases, and foster supportive environments for healthy lifestyles	•	•	•	•	•	•
*protect citizens from serious cross- border health threats (Zika and Ebola outbreaks)	•	•		•	•	•
*contribute to innovative, efficient and sustainable health systems	•	•		•	•	•
*facilitate access to better and safer healthcare for EU citizens	•	0	©	•	•	•
*contribute to addressing health inequalities and the promotion of equity and solidarity	•	•	•	•	•	•

2.2. To what extent do you agree with the following statements about the 3HP?

	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Don't know
--	-------------------	-------	-------------------------------------	----------	----------------------	---------------

*The 3HP's objectives and priorities are clear and easy to understand	©	•	©	•	•	•
*The 3HP's objectives and priorities are in line with the main health needs in Europe and are appropriate for addressing the key issues and challenges	©	•	•	•	•	•
*The objectives and priorities of the 3HP are consistent with health policy objectives in my country	•	•	•	•	•	•
*The more explicit consideration of economic resources and constraints in the objectives of the 3HP (compared with its predecessors) is appropriate	©	©	•	•	•	•
*The objectives and priorities of the 3HP are consistent with wider EU policy objectives, including the Europe 2020 strategy	©	•	©	•	•	•



2.3. I	If you have	any concerns	s about the r	elevance an	d coherence	of the 3HP	and its	objectives
ple	ease briefly	summarise th	nem here.					

2.4. The 3HP contains 23 thematic priorities, gathered under four specific objectives:

- 1. Promote health, prevent diseases, and foster supportive environments for healthy lifestyles
- 2. Protect citizens from serious cross-border health threats
- 3. Contribute to innovative, efficient and sustainable health systems
- 4. Facilitate access to better and safer healthcare for EU citizens

Please select up to five priorities that you consider to be the most important, and up to five that you consider to be not relevant.

	Most important	Not relevant
1.1. Risk factors such as use of tobacco and passive smoking, harmful use of alcohol, unhealthy dietary habits and physical inactivity	0	0
1.2. Drugs-related health damage, including information and prevention	0	0
1.3. HIV/AIDS, tuberculosis and hepatitis	•	0
1.4. Chronic diseases including cancer, age-related diseases and neurodegenerative diseases	•	0
1.5. Tobacco legislation	0	0

1.6. Health information and knowledge system to contribute to evidence-based decision-making	0	0
2.1. Additional capacities of scientific expertise for risk assessment	0	0
2.2. Capacity-building against health threats in Member States, including, where appropriate, cooperation with neighbouring countries	•	0
2.3. Implementation of EU legislation on communicable diseases and other health threats, including those caused by biological and chemical incidents, environment and climate change	©	0
2.4. Health information and knowledge system to contribute to evidence-based decision-making	•	0
3.1. Health Technology Assessment	0	0
3.2. Innovation and e-health	0	0
3.3. Health workforce forecasting and planning	0	0
3.4. Setting up a mechanism for pooling expertise at EU level	0	0
3.5. European Innovation Partnership on Active and Healthy Ageing	0	0
3.6. Implementation of EU legislation in the field of medical devices, medicinal products and cross-border healthcare	•	0
3.7. Health information and knowledge system including support to the Scientific Committees set up in accordance with Commission Decision 2008/721/EC	©	0
4.1. European Reference Networks	0	0
4.2. Rare diseases	•	0
4.3. Patient safety and quality of healthcare	•	0
4.4. Measures to prevent antimicrobial resistance and control healthcare-associated infections	•	0
4.5. Implementation of EU legislation in the fields of tissues and cells, blood, organs	0	0
4.6. Health information and knowledge system to contribute to evidence-based decision-making	0	0

	If there are any other ture, or amendments	•	•	-		should supp	ort in the
III.	IMPLEMENTAT	TION					
	 Cooperation proje Actions jointly un The functioning of Cooperation with Studies and othe policies 	ects at EU leve dertaken by M of non-governr international	el (via proje lember Stat nental bodie organisation	ect grants) se health authores (via operations) se (via direct g	orities ng grants) rants)		EU health
(The 3HP is implemente Commission in consulta Programme Committee Programme; its tasks in monitoring actions and apportunities arising thround here. To what extent do your in the programme of the programme is implemented by the programme is included by th	ttion with repre). An executive clude issuing disseminating ough the Prog	esentatives e agency (C calls and ev the results. gramme. An	of the countries CHAFEA) is res valuating propose National Foca infographic sh	es that participals ponsible for in posals, disbursing Points in Menowing the diff	ate in the 3HP mplementing t ng payments, mber States p erent roles ca	via the he promote n be
		Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly disagree	Don't know

*The types of funding mechanisms used by the 3HP are appropriate to achieve the objectives of the programme	©	©	•	•	•	•
*The prioritised actions in the Annual Work Programme permit the optimal involvement of health actors and stakeholders' groups by making appropriate use of the different funding mechanisms		•		•	•	
*The 3HP includes appropriate measures to involve all Member States, including those with lower incomes	©	•	©	•	•	•
*The more explicit consideration of economic resources and constraints in the objectives of the 3HP (compared with its predecessors) is appropriate	©	©	©	•	•	•
*The level of financial support that the 3HP offers is appropriate to address its objectives	©	•	•	•	•	•

3.2. If you have any (ad please briefly summa correspond to (tick all Eligibility / funding Application proces Administrative bur Dissemination of r Other (please spe	rise them here I that apply): arrangements s den esults cify)	and provi	de us with an	indication of	which area(s) they
	Strongly agree	Agree	Neither agree nor disagree	Disagree	Strongly	Don't know
*The results of actions funded by the 3HP are sufficiently disseminated and promoted to those who might be able to make use of them			•			
3.4. Do you have other to the above question	-	that could	not be expre	ssed in the co	ontext of you	r replies
* There is disse whether the tool involved in the *Translation of policies)	s and resear	cch are re	eally used by	y stakeholde	ers beyond t	chose

*Please indicate whether you are responding to this consultation as an income of the following types of organisations / institutions?	dividual or on behalf of
Individual / private person	
Public authority (national, regional or local)	
International organisation	
Academic / research organisation	
Professional association or trade union	
Non-governmental organisation	
Private company	
Other, please specify	

^ Plea	se state your country of residence/establishment
0	Austria
•	Belgium
	Bulgaria
	Croatia
	Cyprus
	Czech Republic
	Denmark
	Estonia
	Finland
	France
	Germany
	Greece
	Hungary
	Ireland
	Italy
	Latvia
	Lithuania
	Luxembourg
	Malta
	Netherlands
	Poland
	Portugal
0	Romania
0	Slovak Republic
	Slovenia
	Spain
0	Sweden
0	United Kingdom
	Other
	sent in comments in a language other than English, please indicate in which language you
have	replied.

*Which of the following best describes the field in which you or the organisation or institution you are representing are mainly active?
Health / public health policy making and planning
Provision of healthcare services
Health professional(s)
Health research / education
Patients and health service users
Other, please specify
Other, please specify
* First name
Ann Isabelle
* Last name
von Lingen
* Job title
policy officer
Your organisation's name (where relevant)
European AIDS Treatment Group
The number of members your organisation represents (where relevant)
175
Countries where your organisation is present (where relevant)
we are a network of advocates across Europe and Central Asia

*If replying on behalf of an organisation or institutions, is your organisation or institution
registered in the EU Transparency Register?

- Yes
- O No
- Not applicable

If yes please indicate your Register ID number

49959188061-85

If you are responding on behalf of an organisation or institution, please register in the <u>Transparency Register</u>. If your organisation/institution responds without being registered, the Commission will consider its input as that of an individual and will publish it as such.

- * Please indicate your preference for the publication of your response on the Commission's website:
 - I consent to publication of all information in my contribution, including my personal data
 - I do not consent to the publication of my personal data as it would harm my legitimate interests. My contribution may be published in an anonymous form
 - I prefer to keep my contribution confidential. (it will not be published, but will be used when analysing the results of the consultation)

(Please note that regardless of the option chosen, your contribution may be subject to a request for access to documents under <u>Regulation 1049/2001 on public access to European Parliament, Council and Commission documents</u>. In this case the request will be assessed against the conditions set out in the Regulation and in accordance with applicable data protection rules.)

*Copyright clearance

Any submission made by you on this website represents an agreement that the data you submitted will be used by the European Commission for the purposes of the mid-term evaluation of the 3rd Health Programme. This means that your contributions may be published individually or be part of a synthesis and referred to as meaningful example. Following your submission you also understand that you authorise the European Commission to reproduce, translate, print, publish and make available your contributions in print and electronic format and permit others to use the content or parts of it in accordance with Commission Decision of 12 December 2011 on the reuse of Commission Documents.

- I took note of the above copyright clearance conditions and I agree with it
- I don't agree, please keep my contribution as specified under the abovementioned terms, but only for internal use in the Commission

Useful links

<u>Factsheet on the Third Health Programme (http://ec.europa.eu/health/programme/docs/factsheet_healthprogramme2014_2020_en.pdf)</u>

Regulation (EU) No 282/2014 on the establishment of a third Programme for the Union's action in the field of hea (2014-2020) (http://data.europa.eu/eli/reg/2014/282/oj)

Summaries of the Annual Work Programmes for 2014 (http://ec.europa.eu/health/programme/docs/wp2014_annex_summary_en.pdf)

Summaries of the Annual Work Programmes for 2015 (http://ec.europa.eu/health/programme/docs/wp2015_summary_en.pdf)

Summaries of the Annual Work Programmes for 2016 (http://ec.europa.eu/health/programme/docs/wp2016_summary_en.pdf)

Ex-post evaluation of the 2nd Health Programme 2008-2013 (http://ec.europa.eu/health/programme/policy/2008-2013/evaluation en.htm)

Contact

SANTE-HEALTH-PROGRAMME@ec.europa.eu